Intranasal Drug Delivery Devices Market Size, Share and Trends 2026 to 2035

What is the Intranasal Drug Delivery Devices Market Size?

The global intranasal drug delivery devices market size was calculated at USD 1,868.61 million in 2025 and is predicted to increase from USD 2,043.63 million in 2026 to approximately USD 4,949.45 million by 2035, expanding at a CAGR of 10.33% from 2026 to 2035.

Intranasal Drug Delivery Devices Market Key Takeaways

• North America led the market with a 44.91% share in 2025.
• By system, multi-dose systems dominated the market with a 62.06% share in 2025.
• By container, non-pressurized containers led the market with a 68.16% share in 2025.
• By application, allergy & nasal conditions accounted for the largest share at 39.58% in 2025.
• By end-user, hospitals dominated the market with a 42.91% share in 2025.

Intranasal Drug Delivery Devices Market Growth Factors

• Increasing patient preference for nasal drug delivery as a result of easy administration and better efficacy
• High prevalence of cardiovascular diseases
• Patent expiration of popular drugs, increased cases of cancer and diabetes
• Growing Adoption of Self-Administration Practices
• Technological advancements

Major Trends in the Intranasal Drug Delivery Devices Industry

Considering the wide-ranging awareness in nasal drug delivery and the possible advantages of intranasal administration, it is anticipated that novel nasal drug delivery products will continue to arrive at the market and advance exponentially in the forthcoming years. The prospects in the worldwide market for the intranasal drug delivery devices have drawn huge expenditure by major companies in research and development activities.

Moreover, in the emerging countries such as India, China, etc. having low labor and clinical trials costs, will further aidin drawing market players to these nations and will observe an exponential development in the forthcoming years. The novel nasal drug delivery devices are expected to reach the market and grow significantly in the upcoming years due to the prevalent awareness regarding nasal drug delivery and the probable advantages of intranasal administration. The prospects in the global market for the intranasal drug delivery devices have invited huge investments by key companies in the research and development activities.

Furthermore, in the emerging economies in the Asia Pacific region, which have lower costs of clinical trials and labor, will further help to draw market players to this region and will observe an exponential development in the near future. Through the development of spontaneous patient-friendly modernizations, intranasal medication delivery devices and apparatuses enable treatments to remain on the cutting edge along with making life better for affected individuals, thereby offering a great prospect for its overall business to flourish in the forthcoming years. To take completebenefit of these openings offered by nasal delivery of medications, innovative methods to overcome the biological blockades to delivery are being established.

The technological advancements in many of the nasal drug transfer devices currently, consists of the powder preparation and carrier technology, intended for increased medication absorption through its muco-adhesive features and a transfer device technology intended for simple use, and comprehensive and consistent transfer of intranasal powder preparations. This technology can be employed to a wide range of medications, including peptides, small molecules, and biologics.

Market Scope

Segment Insights

System Insights

The multi-dose systems segment held a 62.06% share in 2025. These systems dominate the market due to their cost-effectiveness, convenience, and suitability for long-term treatment of chronic conditions such as allergies and rhinitis. They allow patients to use a single device multiple times, reducing overall treatment costs and improving adherence. Technological advancements, including improved spray mechanisms and dose counters, have enhanced accuracy and safety. Their widespread availability and compatibility with a broad range of drug formulations further strengthen their leading position.

The unit-dose systems segment held a 32.63% share in 2025. These systems are particularly valued for their precision, safety, and reduced risk of contamination, making them ideal for acute and emergency applications. They are widely used in treatments such as opioid overdose reversal and seizure rescue, where accurate dosing is critical. The single-use nature ensures hygiene and reliability, especially in clinical and emergency settings. However, higher per-unit costs compared to multi-dose systems limit their use in long-term therapies.

The hybrid/emerging formats segment held a 5.31% share in 2025. This segment includes innovative systems that combine the advantages of both multi-dose and unit-dose technologies, offering flexibility and improved performance. These formats are gaining traction due to advancements in drug-device integration and smart delivery mechanisms. Although currently a smaller segment, increasing investment in research and development is accelerating innovation. Over time, these emerging systems are expected to capture a larger share as new therapies are developed.

Intranasal Drug Delivery Devices Market By System, 2023-2025 (USD Million)

Container Insights

The non-pressurized containers segment held a 68.16% share in 2025. These containers are widely used due to their simple design, lower manufacturing costs, and ease of use. They are particularly suitable for multi-dose nasal sprays used in treating chronic conditions such as allergies and sinusitis. The absence of propellants reduces safety concerns and environmental impact, making them a preferred choice. Additionally, their compatibility with a wide range of formulations further strengthens their market dominance.

The pressurized containers segment held a 31.84% share in 2025. These systems are designed to deliver highly consistent and controlled doses, making them suitable for specialized and high-precision applications. They are often used in formulations where uniform particle distribution and deep nasal penetration are required. Despite their advantages, higher production costs and complex design limit widespread adoption. However, ongoing technological improvements are expected to enhance their efficiency and expand their applications.

Intranasal Drug Delivery Devices Market By Container, 2023-2025 (USD Million)

Application Insights

Asthma is Projected to Dominate the Application Segment of Intranasal Drug Delivery Devices Market Revenue

The allergy & nasal conditions segment held a 39.58% share in 2025. This segment dominates due to the high global prevalence of allergic rhinitis, sinusitis, and other nasal disorders. Intranasal delivery provides rapid, localized relief with minimal systemic side effects, making it highly effective. Increasing environmental pollution and changing lifestyles are contributing to rising incidence rates. Continuous development of advanced formulations is further driving segment growth.

The migraine rescue segment held a 12.03% share in 2025. Intranasal therapies are gaining popularity for migraine treatment due to their fast onset of action compared to oral medications. They are particularly beneficial for patients experiencing nausea or vomiting during migraine attacks. Increasing awareness, improved diagnosis rates, and availability of targeted therapies are supporting growth. Pharmaceutical advancements are also enhancing efficacy and patient outcomes.

The opioid overdose reversal segment held a 9.23% share in 2025. Intranasal naloxone devices play a critical role in emergency response by enabling rapid and easy administration. Rising opioid abuse and overdose cases globally are major drivers of this segment. Governments and public health organizations are actively promoting the distribution of these devices. Their ease of use by non-medical personnel significantly increases their adoption.

The CNS/psychiatric segment held a 10.78% share in 2025. Intranasal delivery offers a unique advantage by bypassing the blood-brain barrier, allowing faster and more effective drug action. This makes it highly suitable for treating conditions such as depression, anxiety, and other neurological disorders. Increasing research into brain-targeted therapies is expanding the scope of this segment. Growing acceptance among healthcare providers is further boosting adoption.

The seizure rescue segment held a 7.32% share in 2025. Intranasal benzodiazepines provide rapid relief during seizure emergencies, making them highly effective. These devices are easy to administer by caregivers, even outside clinical settings. Increasing awareness and improved access to emergency treatments are driving demand. Regulatory approvals for new formulations are also supporting market growth.

The nasal vaccines segment held a 14.80% share in 2025. These vaccines are gaining attention due to their needle-free administration and improved patient compliance. They stimulate mucosal immunity, which is particularly effective against respiratory infections. Ongoing research and development are expanding their use in infectious disease prevention. Their potential for mass immunization programs further enhances growth prospects.

The others segment held a 6.26% share in 2025. This category includes emerging and niche applications of intranasal drug delivery technologies. Growth is driven by ongoing clinical research and exploration of new therapeutic areas. Pharmaceutical companies are increasingly investing in innovative formulations. Over time, these applications are expected to gain greater market relevance.

Intranasal Drug Delivery Devices Market By Application, 2023-2025 (USD Million)

End User Insights

The hospitals segment held a 42.91% share in 2025. Hospitals are the primary settings for administering advanced intranasal therapies, especially in emergency and critical care situations. The availability of skilled healthcare professionals and advanced infrastructure supports high adoption rates. Hospitals are also early adopters of newly approved devices and technologies. Increasing patient inflow and demand for rapid treatment solutions further strengthen this segment.

The clinics segment held a 27.11% share in 2025. Clinics play a crucial role in managing chronic conditions such as allergies and migraines using intranasal therapies. They offer accessible, cost-effective care and support outpatient treatment models. Increasing patient preference for convenient and quick treatments is boosting this segment. Adoption of user-friendly drug delivery devices is also contributing to growth.

The ambulatory surgical centers segment held a 15.32% share in 2025. These centers focus on providing efficient, minimally invasive procedures with shorter patient stays. Intranasal drug delivery aligns well with their need for quick and effective treatment options. Rising preference for outpatient surgical procedures is driving demand in this segment. Cost efficiency and faster recovery times further support growth.

Intranasal Drug Delivery Devices Market By End User, 2023-2025 (USD Million)

Regional Insights

U.S. Intranasal Drug Delivery Devices Market Size and Growth 2026 to 2035

The U.S. intranasal drug delivery devices market size was estimated at USD 755.99 million in 2025 and is predicted to be worth around USD 1,743.93 million by 2035, at a CAGR of 8.81% from 2026 to 2035.

North America held a 44.91% share in 2025. This leadership position is primarily driven by highly advanced healthcare infrastructure, strong reimbursement frameworks, and early adoption of innovative drug delivery technologies. The region benefits from a high prevalence of respiratory disorders, migraines, and neurological conditions, all of which are increasingly treated using intranasal routes for faster onset of action. Additionally, the presence of major pharmaceutical and device manufacturers, coupled with continuous product approvals and strong regulatory support, reinforces sustained market dominance.

Europe held a 26.56% share in 2025. Growth in this region is supported by well-established public healthcare systems and a rapidly aging population that requires convenient and non-invasive treatment options. Increasing demand for self-administration and home-based care solutions is encouraging the use of intranasal drug delivery devices. Furthermore, regulatory harmonization across the European Union and rising investments in pharmaceutical R&D are accelerating the introduction of advanced nasal drug formulations.

Asia-Pacific held a 21.63% share in 2025. This region is experiencing rapid expansion due to growing healthcare expenditure, large patient populations, and increasing awareness of advanced drug delivery systems. Countries such as China, India, and Japan are investing heavily in healthcare infrastructure and expanding access to modern treatments. In addition, the rising burden of chronic respiratory diseases and neurological disorders, combined with improving regulatory frameworks, is significantly boosting market penetration.

Intranasal Drug Delivery Devices Market Companies

• Johnson & Johnson, Inc.
• Aptar Pharma Group
• GlaxoSmithKline Plc
• Aegis Therapeutics LLC
• H&T Presspart Manufacturing Ltd.
• AstraZeneca Plc
• Becton, Dickinson and Company
• Novartis AG
• Teleflex Incorporated
• Vectura Group Plc.

Segments Covered in the Report

By System

• Multi-Dose Systems
  
  • Liquid-based
    
    • Metered Spray Pumps
    • pMDIs
    • Atomizers
    • Nasal Drops
    • Others
  • Powder-based DPIs
  • Liquid-based Systems

• Unit-Dose Systems
  
  • Liquid-based
    
    • Prefilled Single-use Sprays
    • Single-use Atomizers
    • BFS (Blow-Fill-Seal)
  • Powder-based
    
    • Capsule-based / Single-use DPIs
    • Powder-Nasal Powder Applicators
  • Gel-Single-use Applicators

• Others (Hybrid/Emerging Formats)

By Container

• Non-Pressurized Containers
• Pressurized Containers

By Application

• Allergy & Nasal Conditions
• Migraine Rescue
• Opioid Overdose Reversal
• CNS/Psychiatric
• Seizure Rescue
• Nasal Vaccines
• Others

By End User

• Ambulatory Surgical Centers
• Clinics
• Hospitals
• Others

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa (MEA)